CellRep

Alfonso  Amat; Federico Perdomo-Celis; Manuel  Franco Cortés; Julian  Ganzabal; Luca  Gattinoni

CellRep

Alfonso Amat (Owner)
, Federico Perdomo-Celis (Owner)
, Manuel Franco Cortés (Inventor)
, Julian Ganzabal (Owner)
, Luca Gattinoni (Inventor)

Institute of Human Genetics

Research output: Innovation Products › Spin-off

Abstract

CellRep pioneers dynamic cell reprogramming without gene editing, revolutionizing how cell therapies work. Our AI-powered platform discovers and validates compounds that enhance cellular function, addressing three critical limitations in current CAR-T therapies: poor efficacy in solid tumors, lengthy manufacturing time, and prohibitive costs. We're making personalized medicine truly scalable, starting with cancer treatments and soon expanding into longevity applications.

Original language	English
State	Published - 01 Aug 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@misc{b85211b831dc4f5fae99f2cd846a03e6,

title = "CellRep",

abstract = "CellRep pioneers dynamic cell reprogramming without gene editing, revolutionizing how cell therapies work. Our AI-powered platform discovers and validates compounds that enhance cellular function, addressing three critical limitations in current CAR-T therapies: poor efficacy in solid tumors, lengthy manufacturing time, and prohibitive costs. We're making personalized medicine truly scalable, starting with cancer treatments and soon expanding into longevity applications.",

author = "Alfonso Amat and Federico Perdomo-Celis and \{Franco Cort{\'e}s\}, Manuel and Julian Ganzabal and Luca Gattinoni",

year = "2024",

month = aug,

day = "1",

language = "English",

type = "Patent",

}

TY - PAT

T1 - CellRep

AU - Franco Cortés, Manuel

AU - Gattinoni, Luca

A2 - Amat, Alfonso

A2 - Perdomo-Celis, Federico

A2 - Ganzabal, Julian

PY - 2024/8/1

Y1 - 2024/8/1

N2 - CellRep pioneers dynamic cell reprogramming without gene editing, revolutionizing how cell therapies work. Our AI-powered platform discovers and validates compounds that enhance cellular function, addressing three critical limitations in current CAR-T therapies: poor efficacy in solid tumors, lengthy manufacturing time, and prohibitive costs. We're making personalized medicine truly scalable, starting with cancer treatments and soon expanding into longevity applications.

AB - CellRep pioneers dynamic cell reprogramming without gene editing, revolutionizing how cell therapies work. Our AI-powered platform discovers and validates compounds that enhance cellular function, addressing three critical limitations in current CAR-T therapies: poor efficacy in solid tumors, lengthy manufacturing time, and prohibitive costs. We're making personalized medicine truly scalable, starting with cancer treatments and soon expanding into longevity applications.

UR - https://cellrep.bio/

M3 - Spin-off

ER -

CellRep

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this